Great Valley Advisor Group’s Nymox Pharmaceutical Corp NYMX Stock Holding History

Great Valley Advisor Group’s Portfolio NYMX Stock Details NYMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-10,000	Closed	-$1.9K	–	739
2023 Q2	$1.9K	Hold	10,000	–	–	﹤0.01%	703
2023 Q1	$3.4K	Hold	10,000	–	–	﹤0.01%	697
2022 Q4	$3.23K	Hold	10,000	–	–	﹤0.01%	694
2022 Q3	$4K	Hold	10,000	–	–	﹤0.01%	671
2022 Q2	$4K	Buy	+10,000	New	+$9.2K	﹤0.01%	673

Other funds holding NYMX

DDC

DF Dent & Co Baltimore, Maryland $5.22B AUM 2.07% 1-Year Est. Return

FCFC

First Citizens Financial Corp Mason City, Iowa $239M AUM 26.56% 1-Year Est. Return

CAM

Cubic Asset Management Boston, Massachusetts $422M AUM 29.18% 1-Year Est. Return

ODIJL

One Day In July LLC Burlington, Vermont $1.25B AUM 12.08% 1-Year Est. Return

Great Valley Advisor Group's NYMX Position: Q3 2023 in Review

Great Valley Advisor Group sold out of Nymox Pharmaceutical Corp (NYMX) in Q3 2023, closing a stake of 10,000 shares — an estimated $1.9K sold.

Great Valley Advisor Group first reported a position in NYMX in Q2 2022 and held it in 5 quarters. The position peaked at $4K in Q3 2022. 5 funds tracked by Wall St. Rank hold NYMX as of Q3 2023.

Great Valley Advisor Group reported no remaining Nymox Pharmaceutical Corp position as of Q3 2023 after selling out during the quarter.
Great Valley Advisor Group sold 10,000 Nymox Pharmaceutical Corp shares in Q3 2023, an estimated $1.9K.
Great Valley Advisor Group first reported a position in Nymox Pharmaceutical Corp in Q2 2022 and held it in 5 quarters.
Great Valley Advisor Group's Nymox Pharmaceutical Corp position peaked at $4K in Q3 2022.
5 funds tracked by Wall St. Rank held Nymox Pharmaceutical Corp as of Q3 2023.

Based on Great Valley Advisor Group's 13F filing for Q3 2023, filed 7 Nov 2023.